troglitazone has been researched along with Anasarca in 7 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "60 μmol/cm²) exhibited topical antiedematous properties comparable to those of indomethacin (ID₅₀ 0." | 3.77 | Lignan derivatives from Krameria lappacea roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro. ( Atanasov, AG; Bauer, J; Bauer, R; Baumgartner, L; Bodensieck, A; Dirsch, VM; Fakhrudin, N; Favero, GD; Heiss, EH; Ladurner, A; Loggia, RD; Ponti, C; Rollinger, JM; Schwaiger, S; Sosa, S; Stuppner, H; Tubaro, A; Werz, O; Widowitz, U, 2011) |
| "The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity, although it was judged as safe during the clinical trial." | 2.41 | [Evaluation of thiazolidinedione derivative drugs for safety]. ( Iwata, M; Kobayashi, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prabhakar, C | 1 |
| Madhusudhan, G | 1 |
| Sahadev, K | 1 |
| Reddy, CM | 1 |
| Sarma, MR | 1 |
| Reddy, GO | 1 |
| Chakrabarti, R | 1 |
| Rao, CS | 1 |
| Kumar, TD | 1 |
| Rajagopalan, R | 1 |
| Baumgartner, L | 1 |
| Sosa, S | 1 |
| Atanasov, AG | 1 |
| Bodensieck, A | 1 |
| Fakhrudin, N | 1 |
| Bauer, J | 1 |
| Favero, GD | 1 |
| Ponti, C | 1 |
| Heiss, EH | 1 |
| Schwaiger, S | 1 |
| Ladurner, A | 1 |
| Widowitz, U | 1 |
| Loggia, RD | 1 |
| Rollinger, JM | 1 |
| Werz, O | 1 |
| Bauer, R | 1 |
| Dirsch, VM | 1 |
| Tubaro, A | 1 |
| Stuppner, H | 1 |
| Kotake, D | 1 |
| Hirasawa, N | 1 |
| Kanazawa, A | 1 |
| Kawamori, R | 1 |
| Gorson, DM | 1 |
| King, AB | 1 |
| Kobayashi, M | 1 |
| Iwata, M | 1 |
2 reviews available for troglitazone and Anasarca
| Article | Year |
|---|---|
[Adverse effects of insulin sensitisers and biguanides].
Topics: Acidosis, Lactic; Animals; Biguanides; Capillary Permeability; Chemical and Drug Induced Liver Injur | 2007 |
[Evaluation of thiazolidinedione derivative drugs for safety].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Edema; Heart Fa | 2001 |
1 trial available for troglitazone and Anasarca
| Article | Year |
|---|---|
A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
Topics: Body Weight; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglob | 2000 |
4 other studies available for troglitazone and Anasarca
| Article | Year |
|---|---|
Synthesis and biological activity of novel thiazolidinediones.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Butanones; Chromans; Edema; Female; | 1998 |
Lignan derivatives from Krameria lappacea roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Austria; Benzofurans; | 2011 |
Activation of a retinoic acid receptor pathway by thiazolidinediones induces production of vascular endothelial growth factor/vascular permeability factor in OP9 adipocytes.
Topics: Adipocytes; Animals; Aspirin; Capillary Permeability; Cell Differentiation; Cells, Cultured; Chroman | 2013 |
Significant weight gain with rezulin therapy.
Topics: Chromans; Diabetes Mellitus, Type 2; Edema; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiazole | 1999 |